United StatesÚltimas notícias

Major summits and crucial trade data releases are set to shape a busy week across Asia.

Chinese camera maker Insta360 is stepping up its US drone push as regulators tighten curbs on rival manufacturers.

Singapore Exchange has rolled out crypto futures contracts aimed at institutional traders looking for regulated market access.

The US Senate Banking Committee is advancing sweeping crypto legislation to clarify rules and support domestic digital asset innovation.

Labour MPs are urging the UK government to ban crypto political donations as concerns grow over transparency and election integrity.

USANA Health Sciences (NYSE:USNA), a global leader in nutritional supplements and wellness products sold through direct selling, today announced preliminary fiscal year 2025 net sales results and its initial net sales outlook for fiscal 2026 ahead of its presentation at the 28th Annual ICR Conference.

XPENG (NASDAQ:XPEV) solidified its position as a frontrunner in the global electric vehicle race on Monday, unveiling its 2026 flagship P7+ and a suite of "Physical AI" milestones that signal a decisive shift toward autonomous mobility.

Viridien (NYSE:CCG), the advanced technology and digital data group formerly known as CGG, released a bullish preliminary 2025 update on Monday, showcasing the fruit of its multi-year "asset-light" transformation.

Evolus (NASDAQ:EOLS), a global performance beauty company dedicated to building a differentiated aesthetic portfolio, announced preliminary, unaudited net revenue results for the fourth quarter and full year ended December 31, 2025, along with updated forward-looking guidance.

Amazon Pharmacy (NASDAQ:AMZN), a full-service digital pharmacy that delivers medications directly to customers' homes, now offers Novo Nordisk’s Wegovy® pill, the first and only FDA-approved oral GLP-1 for weight management, through many insurance plans as well as a transparent cash-pay option.

Madrigal Pharmaceuticals (NASDAQ:MDGL) announced it has entered into an exclusive global license agreement with Pfizer (NYSE:PFE) for ervogastat (formerly PF-06865571), an oral diacylglycerol acyltransferase 2 (DGAT-2) inhibitor currently in Phase 2 development, as well as rights to two additional early-stage metabolic dysfunction-associated steatohepatitis (MASH) assets.

Boston-based Rhythm Pharmaceuticals (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity, announced preliminary, unaudited net product revenues for its flagship therapy IMCIVREE (setmelanotide) for the fourth quarter and full year ended December 31, 2025.